Shares in the UK's GW Pharmaceuticals plc have shot up, buoyed by stellar sales of the groundbreaking cannabis-based epilepsy drug Epidiolex (cannabidiol) and the start of Phase III trials of nabiximols for multiple sclerosis spasticity.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?